Ocrelizumab in relapsing-remitting multiple sclerosis: a placebo-controlled, multicentre trial

Lancet, The

378, 1779-1787

Citation Report

#	Article	IF	Citations
2	Multiple sclerosisâ€"quenching the flames of inflammation. Lancet, The, 2011, 378, 1759-1760.	6.3	7
3	Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology, 2011, 258, 1747-1762.	1.8	47
4	Current Theories for Multiple Sclerosis Pathogenesis and Treatment. , 2012, , .		0
5	Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases. Current Pharmaceutical Design, 2012, 18, 4498-4507.	0.9	11
7	Rituximab combination therapy in relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2012, 5, 311-319.	1.5	36
8	Emerging strategies for the treatment of multiple sclerosis. Future Neurology, 2012, 7, 193-207.	0.9	0
9	Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Therapeutic Advances in Hematology, 2012, 3, 199-207.	1.1	7
10	B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms. Biologics: Targets and Therapy, 2012, 6, 117.	3.0	17
11	Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Human Molecular Genetics, 2012, 21, 3575-3586.	1.4	50
12	Interplaying Factors That Effect Multiple Sclerosis Causation and Sustenance. ISRN Neurology, 2012, 2012, 1-27.	1.5	10
15	Ocrelizumab in multiple sclerosis: risks and benefits. Lancet, The, 2012, 379, 1196-1197.	6.3	11
16	<scp>B</scp> cells set trends: Lessons from multiple sclerosis. Clinical and Experimental Neuroimmunology, 2012, 3, 89-108.	0.5	1
17	Rituximab: emerging treatment strategies of immune-mediated glomerular disease. Expert Review of Clinical Immunology, 2012, 8, 413-421.	1.3	10
18	B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nature Reviews Neurology, 2012, 8, 613-623.	4.9	230
19	Evolution of Vertebrate Immunity. Current Biology, 2012, 22, R722-R732.	1.8	115
20	What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?. International Journal of Molecular Sciences, 2012, 13, 12665-12709.	1.8	35
21	Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity, 2012, 45, 400-414.	1.2	52
23	Vaccination against infection in patients with multiple sclerosis. Nature Reviews Neurology, 2012, 8, 143-151.	4.9	85

#	Article	IF	Citations
24	Current and emerging therapies in multiple sclerosis: a systematic review. Therapeutic Advances in Neurological Disorders, 2012, 5, 205-220.	1.5	112
25	Pharmacotherapeuetic Options for the Treatment of Multiple Sclerosis. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S8661.	0.4	4
26	New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Journal of Central Nervous System Disease, 2012, 4, JCNSD.S6692.	0.7	12
27	Immunology of MS. , 0, , 62-89.		0
28	Emerging Disease-Modifying Therapies in Multiple Sclerosis. Current Treatment Options in Neurology, 2012, 14, 256-263.	0.7	19
29	Ethical challenges in paediatric clinical trials in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2012, 5, 139-146.	1.5	11
30	Re‑engineering of pathogenic aquaporin 4‑specific antibodies as molecular decoys to treat neuromyelitis optica. Annals of Neurology, 2012, 71, 287-288.	2.8	9
31	Altered microRNA expression in B lymphocytes in multiple sclerosis. Clinical Immunology, 2012, 144, 70-79.	1.4	111
32	Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome. Journal of Neuroimmunology, 2012, 247, 70-74.	1.1	16
33	B cells in MS: Why, where and how?. Multiple Sclerosis and Related Disorders, 2012, 1, 123-130.	0.9	6
34	Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy, 2013, 13, 831-846.	1.4	14
35	Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation. Journal of Neuroimmunology, 2013, 258, 27-31.	1.1	14
36	Therapeutic Decisions in Multiple Sclerosis. JAMA Neurology, 2013, 70, 1315-24.	4.5	80
37	Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity. BMC Systems Biology, 2013, 7, 34.	3.0	24
38	B-Cell Targeting Agents in the Treatment of Multiple Sclerosis. Current Treatment Options in Neurology, 2013, 15, 259-269.	0.7	9
39	Treatment of Paraneoplastic Cerebellar Degeneration. Current Treatment Options in Neurology, 2013, 15, 185-200.	0.7	44
40	Multiple sclerosis: Prospects and promise. Annals of Neurology, 2013, 74, 317-327.	2.8	165
41	Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis. Drugs, 2013, 73, 1463-1481.	4.9	39

#	ARTICLE	IF	CITATIONS
42	Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study. Arthritis and Rheumatism, 2013, 65, 2368-2379.	6.7	272
43	Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards. Journal of Neural Transmission, 2013, 120, 55-60.	1.4	6
44	Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends in Molecular Medicine, 2013, 19, 309-319.	3.5	85
45	Multiple Sclerosis Immunology. , 2013, , .		7
47	Gene expression analysis of relapsing–remitting, primary progressive and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1841-1848.	1.4	29
48	Emerging injectable therapies for multiple sclerosis. Lancet Neurology, The, 2013, 12, 1115-1126.	4.9	31
49	MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. Journal of Experimental Medicine, 2013, 210, 2921-2937.	4.2	336
50	Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2013, 13, 390.	2.0	7
51	Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. Expert Opinion on Investigational Drugs, 2013, 22, 1243-1253.	1.9	10
52	Multiple sclerosis. Neurology: Clinical Practice, 2013, 3, 404-412.	0.8	0
53	B-cell targeted therapeutics in clinical development. Arthritis Research and Therapy, 2013, 15, S4.	1.6	92
54	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Research and Therapy, 2013, 15, S2.	1.6	109
55	Humoral-Targeted Immunotherapies in Multiple Sclerosis. Neurotherapeutics, 2013, 10, 34-43.	2.1	19
56	Environmental factors and their regulation of immunity in multiple sclerosis. Journal of the Neurological Sciences, 2013, 324, 10-16.	0.3	59
57	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	1.1	14
58	Immunotherapy of Multiple Sclerosis. BioDrugs, 2013, 27, 113-148.	2.2	23
59	Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Review of Neurotherapeutics, 2013, 13, 313-335.	1.4	47
60	Rituximab biosimilars. Expert Opinion on Biological Therapy, 2013, 13, 1049-1062.	1.4	34

#	ARTICLE	IF	CITATIONS
62	Update on immunopathogenesis and immunotherapy in multiple sclerosis. ImmunoTargets and Therapy, 2013, 2, 21.	2.7	17
63	MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurology, The, 2013, 12, 669-676.	4.9	234
64	Drugs in Development for Relapsing Multiple Sclerosis. Drugs, 2013, 73, 625-650.	4.9	53
65	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20200-20205.	3.3	185
66	Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. Multiple Sclerosis Journal, 2013, 19, 863-870.	1.4	18
67	The Road Not Taken. JAMA Neurology, 2013, 70, 1100.	4.5	12
68	Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Therapeutic Advances in Neurological Disorders, 2013, 6, 161-173.	1.5	103
69	Present and Emerging Therapies for Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 968-991.	0.4	11
70	Revisiting the role of BÂcells in multiple sclerosis: Regulatory BÂcell function and defects in peripheral BÂcell tolerance. Clinical and Experimental Neuroimmunology, 2013, 4, 251-252.	0.5	0
71	Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Annals of Neurology, 2013, 73, 86-94.	2.8	38
72	Fingolimod for the treatment of relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 2013, 13, 589-602.	1.4	10
73	Piet Mondrianâ€™s trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011. Multiple Sclerosis Journal, 2013, 19, 5-14.	1.4	7
75	Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations. Canadian Journal of Neurological Sciences, 2013, 40, 307-323.	0.3	178
76	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment, 2013, 9, 893.	1.0	28
77	Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics: Targets and Therapy, 2013, 7, 247.	3.0	40
78	Secondary B Cell Receptor Diversification Is Necessary for T Cell Mediated Neuro-Inflammation during Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2013, 8, e61478.	1.1	12
79	Which Immune Cells Matter? The Immunopathogenesis of Multiple Sclerosis. Critical Reviews in Immunology, 2013, 33, 283-306.	1.0	35
80	Oligodendrocyte Metabolic Stress in Neurodegeneration. , 0, , .		1

#	Article	IF	Citations
81	Alemtuzumab in the treatment of multiple sclerosis. Journal of Inflammation Research, 2014, 7, 19.	1.6	9
82	Novel therapeutic options for multiple sclerosis. Expert Review of Clinical Pharmacology, 2014, 7, 91-104.	1.3	22
83	Therapeutic strategies for relapsing–remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy. Expert Review of Neurotherapeutics, 2014, 14, 1417-1428.	1.4	5
85	The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2014, 7, 7-21.	1.5	34
86	Regulatory genomic regions active in immune cell types explain a large proportion of the genetic risk of multiple sclerosis. Journal of Human Genetics, 2014, 59, 211-215.	1.1	6
87	BG-12 (dimethyl fumarate) in the treatment of multiple sclerosis. Clinical Investigation, 2014, 4, 441-451.	0.0	0
89	Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clinical and Experimental Immunology, 2014, 176, 135-148.	1.1	8
90	In multiple sclerosis, oligoclonal bands connect to peripheral B‑cell responses. Annals of Neurology, 2014, 75, 266-276.	2.8	73
91	Intrathecal anti‑CD 20 efficiently depletes meningeal B cells in CNS autoimmunity. Annals of Clinical and Translational Neurology, 2014, 1, 490-496.	1.7	23
92	Targeting B Cells in Neurological Autoimmune Diseases. Milestones in Drug Therapy, 2014, , 219-246.	0.1	0
93	Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis. Neurology, 2014, 82, 573-581.	1.5	249
94	New management algorithms in multiple sclerosis. Current Opinion in Neurology, 2014, 27, 246-259.	1.8	95
95	The Plasma Cell Signature in Autoimmune Disease. Arthritis and Rheumatology, 2014, 66, 173-184.	2.9	47
96	Current Understanding on the Role of Standard and Immunoproteasomes in Inflammatory/Immunological Pathways of Multiple Sclerosis. Autoimmune Diseases, 2014, 2014, 1-12.	2.7	27
97	Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Science Translational Medicine, 2014, 6, 248ra106.	5.8	194
98	Trial and error in clinical studies: lessons from ATAMS. Lancet Neurology, The, 2014, 13, 340-341.	4.9	17
99	Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurology, The, 2014, 13, 353-363.	4.9	271
100	Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Experimental Neurology, 2014, 262, 8-17.	2.0	136

#	Article	IF	Citations
101	CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. Journal of Neuroinflammation, 2014, 11, 18.	3.1	25
102	Teriflunomide and Its Mechanism of Action in Multiple Sclerosis. Drugs, 2014, 74, 659-674.	4.9	274
103	B cells in Multiple Sclerosis: Good or bad guys?. European Journal of Immunology, 2014, 44, 1247-1250.	1.6	16
104	To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 271-279.	1.4	41
105	B cells in MS and NMO: pathogenesis and therapy. Seminars in Immunopathology, 2014, 36, 339-350.	2.8	72
106	Mode of action and clinical studies with alemtuzumab. Experimental Neurology, 2014, 262, 37-43.	2.0	51
107	Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clinical and Experimental Immunology, 2014, 175, 359-372.	1.1	38
108	Immunology of Relapse and Remission in Multiple Sclerosis. Annual Review of Immunology, 2014, 32, 257-281.	9.5	261
109	DNase hypersensitive sites and association with multiple sclerosis. Human Molecular Genetics, 2014, 23, 942-948.	1.4	21
111	Antiâ€CD20 inhibits T cellâ€mediated pathology and microgliosis in the rat brain. Annals of Clinical and Translational Neurology, 2014, 1, 659-669.	1.7	16
112	Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients. Journal of Immunology, 2014, 193, 580-586.	0.4	223
114	Immunomodulatory activity of interferonâ€beta. Annals of Clinical and Translational Neurology, 2014, 1, 622-631.	1.7	105
115	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. Journal of Clinical Neuroscience, 2014, 21, 1847-1856.	0.8	22
116	Interview: Experiences targeting B cells for the treatment of multiple sclerosis. Immunotherapy, 2014, 6, 127-130.	1.0	1
117	Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis. Clinical Immunology, 2014, 155, 198-208.	1.4	40
118	New and emerging immuneâ€targeted drugs for the treatment of multiple sclerosis. British Journal of Clinical Pharmacology, 2014, 78, 33-43.	1.1	5
119	CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis. Journal of Neuroimmunology, 2014, 274, 230-233.	1.1	4
120	Monoclonal antibodies in treatment of multiple sclerosis. Clinical and Experimental Immunology, 2014, 175, 373-384.	1.1	56

#	ARTICLE	IF	CITATIONS
121	Metabolic and safety issues for multiple sclerosis pharmacotherapy â€" opportunities for personalised medicine. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1145-1159.	1.5	3
122	Established and novel diseaseâ€modifying treatments in multiple sclerosis. Journal of Internal Medicine, 2014, 275, 350-363.	2.7	114
123	Disease-modifying agents in multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 465-501.	1.0	10
124	A changing treatment landscape for multiple sclerosis: challenges and opportunities. Journal of Internal Medicine, 2014, 275, 364-381.	2.7	50
126	CD19 as a molecular target in CNS autoimmunity. Acta Neuropathologica, 2014, 128, 177-190.	3.9	22
127	The experimental autoimmune encephalomyelitis (EAE) model of MS. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 173-189.	1.0	348
128	Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. Clinical Immunology, 2014, 151, 127-135.	1.4	52
129	Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis. CNS Drugs, 2014, 28, 535-558.	2.7	26
130	Future treatment approaches to multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 563-577.	1.0	14
131	Demyelination in multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 89-99.	1.0	69
132	Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. Expert Review of Clinical Immunology, 2014, 10, 1281-1291.	1.3	13
133	Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opinion on Biological Therapy, 2014, 14, 503-513.	1.4	12
134	The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. Clinical Immunology, 2014, 151, 16-24.	1.4	49
135	Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis. Journal of Neuroimmunology, 2014, 268, 58-63.	1.1	6
136	Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies. Mayo Clinic Proceedings, 2014, 89, 225-240.	1.4	364
137	Molecular targeted therapy against <scp>B</scp> cells in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 16-27.	0.5	4
138	Multiple Sclerosis: Overview of Disease-Modifying Agents. Perspectives in Medicinal Chemistry, 2014, 6, PMC.S13213.	4.6	40
139	B-cell function modulation in multiple sclerosis: a new therapeutic paradigm. Future Neurology, 2014, 9, 23-26.	0.9	0

#	ARTICLE	IF	CITATIONS
140	Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. The Cochrane Library, 2015, 2015, CD011381.	1.5	131
141	Established, new and future disease modifying therapies for MS. Progress in Neurology and Psychiatry, 2015, 19, 27-35.	0.4	6
142	A basic overview of multiple sclerosis immunopathology. European Journal of Neurology, 2015, 22, 3-13.	1.7	158
143	Novel and imminently emerging treatments in relapsing–remitting multiple sclerosis. Current Opinion in Neurology, 2015, 28, 230-236.	1.8	7
144	Monoclonal Antibodies for Multiple Sclerosis Treatment. Acta Medica Portuguesa, 2015, 28, 640-651.	0.2	2
145	B Cells and Autoantibodies in Multiple Sclerosis. International Journal of Molecular Sciences, 2015, 16, 16576-16592.	1.8	46
146	The Role of Latently Infected B Cells in CNS Autoimmunity. Frontiers in Immunology, 2015, 6, 544.	2.2	27
147	The Ins and Outs of B Cells in Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 565.	2.2	54
148	B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Frontiers in Immunology, 2015, 6, 636.	2.2	120
149	B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Frontiers in Immunology, 2015, 6, 642.	2.2	68
150	Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?. PLoS ONE, 2015, 10, e0116559.	1.1	11
151	Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2015, 10, e0144847.	1.1	12
152	Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nature Reviews Neurology, 2015, 11, 379-389.	4.9	107
153	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Review of Neurotherapeutics, 2015, 15, 251-268.	1.4	4
155	Pathophysiologisch ansetzende Therapie. , 2015, , 267-359.		0
156	The effect of B-cell depletion in the Theiler's model of multiple sclerosis. Journal of the Neurological Sciences, 2015, 359, 40-47.	0.3	18
157	Fulminant Demyelinating Diseases of the Central Nervous System. Seminars in Neurology, 2015, 35, 656-666.	0.5	17
158	Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Review of Clinical Immunology, 2015, 11, 93-108.	1.3	16

#	ARTICLE	IF	CITATIONS
159	Novel therapies for memory cells in autoimmune diseases. Clinical and Experimental Immunology, 2015, 180, 353-360.	1.1	22
160	Multiple sclerosisâ€"a quiet revolution. Nature Reviews Neurology, 2015, 11, 134-142.	4.9	286
161	Natalizumab analogon therapy is effective in a <scp>B</scp> cellâ€dependent multiple sclerosis model. Neuropathology and Applied Neurobiology, 2015, 41, 814-831.	1.8	6
162	The conundrum of interferon-Î² non-responsiveness in relapsingâ€"remitting multiple sclerosis. Cytokine, 2015, 74, 228-236.	1.4	4
163	Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing. Expert Review of Clinical Pharmacology, 2015, 8, 283-296.	1.3	6
164	Immunopathology of multiple sclerosis. Nature Reviews Immunology, 2015, 15, 545-558.	10.6	1,642
165	MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. Gene, 2015, 572, 191-197.	1.0	17
166	A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opinion on Drug Safety, 2015, 14, 1157-1168.	1.0	3
167	MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a. Journal of Neuroimmunology, 2015, 278, 185-189.	1.1	56
168	The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Current Treatment Options in Neurology, 2015, 17, 354.	0.7	51
169	Therapeutic interference with leukocyte recirculation in multiple sclerosis. European Journal of Neurology, 2015, 22, 434-442.	1.7	9
170	Tratamiento de la esclerosis mÃºltiple. Medicine, 2015, 11, 4622-4633.	0.0	0
171	Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology, 2015, 85, 18-28.	1.5	247
172	Disease-modifying therapy for multiple sclerosis. Future Neurology, 2015, 10, 253-279.	0.9	0
173	Update on treatments in multiple sclerosis. Presse Medicale, 2015, 44, e137-e151.	0.8	32
174	Teriflunomide for the treatment of relapsingâ€"remitting multiple sclerosis. Expert Review of Clinical Immunology, 2015, 11, 181-194.	1.3	4
175	Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets. European Neurology, 2015, 73, 238-246.	0.6	1,056
176	Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS?. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e84.	3.1	2

#	Article	IF	Citations
178	Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Therapeutic Advances in Neurological Disorders, 2015, 8, 274-293.	1.5	37
179	Proinflammatory GM-CSFâ€"producing B cells in multiple sclerosis and B cell depletion therapy. Science Translational Medicine, 2015, 7, 310ra166.	5.8	334
180	Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics, 2015, 12, 896-909.	2.1	170
181	The Charcot Lecture	Beating MS: A story of B cells, with twists and turns. Multiple Sclerosis Journal, 2015, 21, 8-21.	1.4	91
182	Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1131-1138.	1.4	41
183	Current Role of Chemotherapy and Bone Marrow Transplantation in Multiple Sclerosis. Current Treatment Options in Neurology, 2015, 17, 324.	0.7	3
185	Clinical Efficacy of Plasma-Exchange in Patients with Progressive forms of Multiple Sclerosis and NMO-Spectrum Disease. Journal of Multiple Sclerosis, 2016, 03, .	0.1	0
186	Environmental Factors and Their Regulation of Immunity in Multiple Sclerosis. , 2016, , 99-111.		1
187	Emerging Therapies for Multiple Sclerosis. , 2016, , 285-304.		0
188	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics: Targets and Therapy, 2016, Volume 10, 119-138.	3.0	7
189	The Immunobiology of Multiple Sclerosis. , 2016, , 180-191.		2
190	Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 626.	2.2	69
191	Antibodies in multiple sclerosis oligoclonal bands target debris. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7696-7698.	3.3	37
192	OMIPâ€"033: A comprehensive single step staining protocol for human Tâ€•and Bâ€•cell subsets. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 629-632.	1.1	10
194	B cell-derived transforming growth factor-Î²1 expression limits the induction phase of autoimmune neuroinflammation. Scientific Reports, 2016, 6, 34594.	1.6	56
195	Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?. Expert Review of Clinical Immunology, 2016, 12, 489-491.	1.3	0
196	Personalized therapy in multiple sclerosis: state of art and future perspectives. Expert Review of Precision Medicine and Drug Development, 2016, 1, 353-360.	0.4	2
197	B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity. Scientific Reports, 2016, 6, 29699.	1.6	34

#	Article	IF	Citations
198	Targeting â€œbadâ€•B cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e283.	3.1	0
199	Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathologica, 2016, 132, 43-58.	3.9	75
200	CNS accumulation of regulatory B cells is VLA-4-dependent. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e212.	3.1	27
201	Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010â€"2015. Expert Review of Neurotherapeutics, 2016, 16, 689-700.	1.4	14
202	A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. Multiple Sclerosis Journal, 2016, 22, 1071-1079.	1.4	34
203	An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Therapeutic Advances in Neurological Disorders, 2016, 9, 180-188.	1.5	47
204	Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies. Seminars in Neurology, 2016, 36, 140-147.	0.5	9
205	Rescue Therapy Using Rituximab for Multiple Sclerosis. Clinical Neuropharmacology, 2016, 39, 178-181.	0.2	16
206	Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis. , 2016, , 175-220.		4
207	A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis â€" Rationale and design. Multiple Sclerosis and Related Disorders, 2016, 9, 95-100.	0.9	15
208	CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis â€" Targeting T or B cells?. Multiple Sclerosis and Related Disorders, 2016, 9, 110-117.	0.9	19
209	Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. The Cochrane Library, 0, , .	1.5	2
210	The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics, 2016, 16, 1341-1356.	1.4	7
211	Effetti collaterali delle bioterapie nella sclerosi multipla e nelle malattie correlate. EMC - Neurologia, 2016, 16, 1-10.	0.0	0
212	Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e272.	3.1	31
213	Features of Human CD3+CD20+ T Cells. Journal of Immunology, 2016, 197, 1111-1117.	0.4	144
214	Ibudilast for the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs, 2016, 25, 1231-1237.	1.9	18
215	Illuminating vitamin D effects on B cells â€" the multiple sclerosis perspective. Immunology, 2016, 147, 275-284.	2.0	50

#	ARTICLE	IF	CITATIONS
216	Effect of interferon-Î²1Î± therapy on multiple sclerosis based on gadolinium-enhancing or active T2 magnetic resonance imaging outcomes: a meta-analysis. Neurological Research, 2016, 38, 909-915.	0.6	1
217	Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein. Journal of Neuroimmunology, 2016, 300, 66-73.	1.1	2
218	Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2016, 15, 1148-1159.	4.9	52
219	Bâ€cellâ€targeted therapy in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2016, 7, 260-271.	0.5	1
220	Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 1131-1139.	1.4	17
221	Focused Ultrasound Treatment of Cervical Lymph Nodes in Rats with EAE: A Pilot Study. Ultrasound in Medicine and Biology, 2016, 42, 2957-2964.	0.7	1
222	Longâ€term evolution of multiple sclerosis disability in the treatment era. Annals of Neurology, 2016, 80, 499-510.	2.8	331
223	The link of inflammation and neurodegeneration in progressive multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	50
224	Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology, 2016, 87, 141-147.	1.5	74
225	B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence. CNS Drugs, 2016, 30, 1137-1148.	2.7	48
226	GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. Immunity, 2016, 45, 963-973.	6.6	417
227	Rituximab in multiple sclerosis. Neurology, 2016, 87, 2074-2081.	1.5	278
228	Rituximab for treating multiple sclerosis. Neurology, 2016, 87, 2070-2071.	1.5	11
229	Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination. Journal of Visualized Experiments, 2016, , .	0.2	6
230	Cytokineâ€producing B cells: aâtranslational view on their roles in human and mouse autoimmune diseases. Immunological Reviews, 2016, 269, 130-144.	2.8	50
231	Placebo-controlled study in neuromyelitis opticaâ€"Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	1.4	63
232	Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Multiple Sclerosis and Related Disorders, 2016, 9, 23-30.	0.9	100
233	The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. Clinical Immunology, 2016, 163, 96-107.	1.4	22

#	Article	IF	Citations
234	Epstein–Barr virus and multiple sclerosis. From evidence to therapeutic strategies. Journal of the Neurological Sciences, 2016, 361, 213-219.	0.3	52
235	B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. Journal of Neuroimmunology, 2016, 291, 46-53.	1.1	22
236	Disease activity return after natalizumab cessation in multiple sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 587-594.	1.4	29
237	B cell-directed therapies in multiple sclerosis. Neurodegenerative Disease Management, 2016, 6, 37-47.	1.2	30
238	Nano- and micro-based systems for immunotolerance induction in multiple sclerosis. Human Vaccines and Immunotherapeutics, 2016, 12, 1-5.	1.4	7
239	Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opinion on Biological Therapy, 2016, 16, 827-839.	1.4	21
240	Disease-modifying therapies and infectious risks in multiple sclerosis. Nature Reviews Neurology, 2016, 12, 217-233.	4.9	199
241	Mécanismes immunologiques des traitements de fond de la sclérose en plaques. Pratique Neurologique - FMC, 2016, 7, 159-165.	0.1	0
242	The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders, 2016, 9, 44-52.	1.5	103
243	Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics, 2016, 13, 20-33.	2.1	25
244	Reducing clinical trial risk in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 5, 81-88.	0.9	7
245	Novel Agents for Relapsing Forms of Multiple Sclerosis. Annual Review of Medicine, 2016, 67, 309-321.	5.0	35
246	Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics, 2016, 13, 84-95.	2.1	49
247	Antibody therapies in CNS diseases. Neuropharmacology, 2017, 120, 38-55.	2.0	96
248	Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications. Journal of Neuroscience Research, 2017, 95, 1973-1983.	1.3	34
249	Emerging Therapies in Multiple Sclerosis. , 2017, , 99-113.		0
250	Infectious Complications of Novel Multiple Sclerosis Therapies. Current Infectious Disease Reports, 2017, 19, 7.	1.3	11
251	Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. Rheumatology International, 2017, 37, 1053-1064.	1.5	14

#	ARTICLE	IF	CITATIONS
252	Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine, 2017, 16, 41-50.	2.7	225
253	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane Library, 2017, 4, CD012200.	1.5	20
254	Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1â€"Mechanisms, Efficacy, and Safety. American Journal of Neuroradiology, 2017, 38, 1664-1671.	1.2	8
255	Multiple Sclerosis: Clinical Features, Immunopathogenesis, and Treatment. , 2017, , 25-75.		1
256	Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. Current Treatment Options in Neurology, 2017, 19, 19.	0.7	5
257	Effector and regulatory B cells in Multiple Sclerosis. Clinical Immunology, 2017, 184, 11-25.	1.4	64
258	Defining Disease Activity and Response to Therapy in MS. Current Treatment Options in Neurology, 2017, 19, 20.	0.7	19
259	Overexpression of the Cytokine BAFF and Autoimmunity Risk. New England Journal of Medicine, 2017, 376, 1615-1626.	13.9	301
260	Immunopathology of the Nervous System. Molecular and Integrative Toxicology, 2017, , 123-219.	0.5	0
261	Ocrelizumab: First Global Approval. Drugs, 2017, 77, 1035-1041.	4.9	31
262	A meta-analysis to determine the efficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosis. Experimental and Therapeutic Medicine, 2017, 13, 3061-3066.	0.8	1
263	Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurology, 2017, 74, 961.	4.5	204
264	Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e360.	3.1	121
265	Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathologica Communications, 2017, 5, 25.	2.4	51
266	Onset of secondary progressive <scp>MS</scp> after longâ€term rituximab therapy â€" a case report. Annals of Clinical and Translational Neurology, 2017, 4, 46-52.	1.7	22
267	Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 476-480.	1.0	17
268	Pediatric Multiple Sclerosis. Current Pediatrics Reports, 2017, 5, 6-12.	1.7	0
269	Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. CNS Drugs, 2017, 31, 357-371.	2.7	11

#	ARTICLE	IF	CITATIONS
270	Monoclonal antibodies in the treatment of multiple sclerosis: emergence of Bâ€cellâ€targeted therapies. British Journal of Pharmacology, 2017, 174, 1895-1907.	2.7	17
271	Immunomodulatory Therapy for Multiple Sclerosis. , 2017, , 713-736.		0
272	Depletion of <scp>CD</scp>52â€positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immuneâ€tolerance promoting <scp>CD</scp>8 Tâ€cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology, 2017, 150, 444-455.	2.0	43
273	A studentized permutation test for threeâ€arm trials in the â€˜gold standardâ€™ design. Statistics in Medicine, 2017, 36, 883-898.	0.8	13
274	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	13.9	1,322
275	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	13.9	1,324
276	Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. Journal of Immunology, 2017, 198, 691-698.	0.4	112
277	Treatment and disease management of multiple sclerosis patients. Journal of the American Association of Nurse Practitioners, 2017, 29, 629-638.	0.5	17
278	Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. Seminars in Pediatric Neurology, 2017, 24, 214-228.	1.0	5
279	Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies. Current Neurology and Neuroscience Reports, 2017, 17, 88.	2.0	71
280	Efficacy of the Treatments Used in Multiple Sclerosis: From Meta-analysis to Number Needed to Treat. Clinical Neuropharmacology, 2017, 40, 37-42.	0.2	0
281	Formulary Drug Review: Ocrelizumab. Hospital Pharmacy, 2017, 52, 599-606.	0.4	0
282	Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmunity Highlights, 2017, 8, 12.	3.9	137
283	B-cellâ€"targeted therapies in relapsing forms of MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e405.	3.1	10
284	Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 196-201.	0.9	13
285	Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics, 2017, 14, 835-841.	2.1	141
286	Activation of human B cells negatively regulates TGF-Î²1 production. Journal of Neuroinflammation, 2017, 14, 13.	3.1	15
287	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opinion on Biological Therapy, 2017, 17, 1163-1172.	1.4	28

#	ARTICLE	IF	CITATIONS
288	Safety of monoclonal antibodies for the treatment of multiple sclerosis. Expert Opinion on Drug Safety, 2017, 16, 89-100.	1.0	27
289	Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 802-809.	1.4	36
290	Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis. Journal of Neuroimmunology, 2017, 304, 56-62.	1.1	10
291	Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic Advances in Neurological Disorders, 2017, 10, 51-66.	1.5	62
292	Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 359-371.	1.4	38
293	Peripheral VH4+Âplasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. Acta Neuropathologica, 2017, 133, 43-60.	3.9	30
294	Safety concerns and risk management of multiple sclerosis therapies. Acta Neurologica Scandinavica, 2017, 136, 168-186.	1.0	65
295	Peptides Against Autoimmune Neurodegeneration. Current Medicinal Chemistry, 2017, 24, 1761-1771.	1.2	4
296	5. Erkrankungen des Rückenmarks und der Cauda equina. , 2017, , 263-386.		0
298	Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. Degenerative Neurological and Neuromuscular Disease, 2017, Volume 7, 31-45.	0.7	5
299	Current concepts in multiple sclerosis therapy. Degenerative Neurological and Neuromuscular Disease, 2017, Volume 7, 109-125.	0.7	13
300	Deciphering the Role of B Cells in Multiple Sclerosis—Towards Specific Targeting of Pathogenic Function. International Journal of Molecular Sciences, 2017, 18, 2048.	1.8	70
301	Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sciences, 2017, 7, 78.	1.1	197
302	Thérapeutiques et prise en charge de la sclérose en plaques. , 2017, , 145-216.		1
303	Novel pathomechanisms in inflammatory neuropathies. Journal of Neuroinflammation, 2017, 14, 232.	3.1	29
304	B cells in multiple sclerosis therapy-A comprehensive review. Acta Neurologica Scandinavica, 2018, 137, 544-556.	1.0	45
305	Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes. Multiple Sclerosis Journal, 2018, 24, 1157-1159.	1.4	9
306	Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Annals of Neurology, 2018, 83, 739-755.	2.8	219

#	ARTICLE	IF	CITATIONS
307	Alemtuzumab as Treatment for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032029.	2.9	22
308	B cells in multiple sclerosis. Current Opinion in Neurology, 2018, 31, 256-262.	1.8	48
309	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. British Journal of Cancer, 2018, 118, 679-697.	2.9	17
310	Western lifestyle and immunopathology of multiple sclerosis. Annals of the New York Academy of Sciences, 2018, 1417, 71-86.	1.8	43
311	Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?. Expert Review of Neurotherapeutics, 2018, 18, 203-219.	1.4	8
312	A Preclinical Population Pharmacokinetic Model for Anti–CD20/CD3 T–Cell–Dependent Bispecific Antibodies. Clinical and Translational Science, 2018, 11, 296-304.	1.5	22
313	Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis. Immunology and Cell Biology, 2018, 96, 160-174.	1.0	93
314	Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS). Cold Spring Harbor Perspectives in Medicine, 2018, 8, a028977.	2.9	139
315	Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e431.	3.1	29
316	Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. Neurology, 2018, 90, e1805-e1814.	1.5	165
317	B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876169.	1.5	67
318	A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurologica Belgica, 2018, 118, 161-168.	0.5	6
319	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	0.5	32
320	Editors' Welcome. Multiple Sclerosis and Related Disorders, 2018, 19, A1-A2.	0.9	0
321	Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy, 2018, 10, 713-728.	1.0	93
322	Rituximab before and during pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e453.	3.1	159
323	Multiple Sclerosis: B Cells Take Center Stage. Journal of Neuro-Ophthalmology, 2018, 38, 251-258.	0.4	14
324	Modulating inflammation and neuroprotection in multiple sclerosis. Journal of Neuroscience Research, 2018, 96, 927-950.	1.3	29

#	ARTICLE	IF	CITATIONS
325	Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis Journal, 2018, 24, 1087-1095.	1.4	44
326	B cells and their cytokine activities implications in human diseases. Clinical Immunology, 2018, 186, 26-31.	1.4	44
327	Progressive Multiple Sclerosis. , 2018, , .		1
328	Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis. Annals of Pharmacotherapy, 2018, 52, 473-483.	0.9	18
329	Trials of Licenced RRMS DMTs in Progressive MS. , 2018, , 207-232.		0
330	A review on nanotechnology based innovations in diagnosis and treatment of multiple sclerosis. Journal of Cellular Immunotherapy, 2018, 4, 56-64.	0.6	38
331	B‐cell Therapy for Multiple Sclerosis: Entering an era. Annals of Neurology, 2018, 83, 13-26.	2.8	179
332	New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis. Neurologic Clinics, 2018, 36, 173-183.	0.8	7
333	Signaling via toll-like receptor 4 and CD40 in B cells plays a regulatory role in the pathogenesis of multiple sclerosis through interleukin-10 production. Journal of Autoimmunity, 2018, 88, 103-113.	3.0	42
334	Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. Current Medical Research and Opinion, 2018, 34, 1361-1371.	0.9	61
335	Model Systems to Define Remyelination Therapies. , 2018, , .		0
336	A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis. Journal of Clinical Medicine Research, 2018, 10, 88-105.	0.6	33
337	Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis. Frontiers in Neurology, 2018, 9, 973.	1.1	8
338	Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients. Scientific Reports, 2018, 8, 17418.	1.6	42
339	B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate. Multiple Sclerosis and Related Disorders, 2018, 26, 90-95.	0.9	12
340	Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages. BMC Neurology, 2018, 18, 162.	0.8	23
341	Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs, 2018, 78, 1549-1566.	4.9	36
342	Emerging Role of Follicular T Helper Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. International Journal of Molecular Sciences, 2018, 19, 3233.	1.8	23

#	ARTICLE	IF	CITATIONS
343	Distinct roles for Blimp-1 in autoreactive CD4 T cells during priming and effector phase of autoimmune encephalomyelitis. Journal of Neuroimmunology, 2018, 325, 20-28.	1.1	3
344	Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9773-9778.	3.3	82
345	Present Drug Therapy of Demyelinating Disorders. Current Drug Therapy, 2018, 13, 25-42.	0.2	0
346	Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain, 2018, 141, 2834-2847.	3.7	43
347	Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis. Multiple Sclerosis and Related Disorders, 2018, 25, 322-328.	0.9	13
349	Ocrelizumab: A Review in Multiple Sclerosis. CNS Drugs, 2018, 32, 883-890.	2.7	49
350	Ocrelizumab: a new milestone in multiple sclerosis therapy. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877302.	1.5	90
351	How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update. Revue Neurologique, 2018, 174, 429-440.	0.6	6
352	Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. Clinical Therapeutics, 2018, 40, 926-939.	1.1	8
353	Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. , 2018, , 1-103.		0
354	New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1093-1099.	1.0	15
355	Role of TFH Cells in Promoting T Helper 17-Induced Neuroinflammation. Frontiers in Immunology, 2018, 9, 382.	2.2	54
356	Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS ONE, 2018, 13, e0190425.	1.1	44
357	Multiple sclerosis pathogenesis: missing pieces of an old puzzle. Reviews in the Neurosciences, 2018, 30, 67-83.	1.4	16
358	Reassessing B cell contributions in multiple sclerosis. Nature Immunology, 2018, 19, 696-707.	7.0	275
359	2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. European Thyroid Journal, 2019, 8, 173-185.	1.2	44
360	Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology, 2019, 10, 1564.	2.2	117
361	Impact of B cells to the pathophysiology of multiple sclerosis. Journal of Neuroinflammation, 2019, 16, 128.	3.1	60

#	Article	IF	Citations
363	Fingolimod Immune Effects Beyond Its Sequestration Ability. Neurology and Therapy, 2019, 8, 231-240.	1.4	22
364	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. Science Translational Medicine, 2019, 11, .	5.8	45
366	Ocrelizumab for multiple sclerosis. The Cochrane Library, 2019, , .	1.5	1
367	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology, 2019, 93, e1778-e1786.	1.5	37
368	Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. Multiple Sclerosis and Related Disorders, 2019, 36, 101419.	0.9	15
369	Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis. Immunopharmacology and Immunotoxicology, 2019, 41, 7-15.	1.1	6
370	Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis. Brain Pathology, 2019, 29, 640-657.	2.1	20
371	Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance. Journal of Immunology, 2019, 202, 1373-1382.	0.4	46
372	For Massachusetts Eye and Ear Special Issue: Updates on Therapies for Multiple Sclerosis for the Ophthalmologist. Seminars in Ophthalmology, 2019, 34, 270-278.	0.8	3
373	Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 19-25.	0.9	13
374	Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 417-429.	1.4	2
375	B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. Journal of Neuroimmunology, 2019, 332, 187-197.	1.1	39
376	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmunity Reviews, 2019, 18, 665-672.	2.5	25
377	The 20-year history: Change of multiple sclerosis patient profile over 20 years. Multiple Sclerosis and Related Disorders, 2019, 33, 1-4.	0.9	5
378	Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. New England Journal of Medicine, 2019, 380, 2406-2417.	13.9	219
379	Glial cells as therapeutic targets in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 481-494.	1.4	10
380	CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opinion on Biological Therapy, 2019, 19, 829-843.	1.4	34
381	Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. Drug Safety, 2019, 42, 941-956.	1.4	12

#	ARTICLE	IF	CITATIONS
382	The role of vitamin D and P2X7R in multiple sclerosis. Journal of Neuroimmunology, 2019, 330, 159-169.	1.1	6
383	Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines, 2019, 7, 20.	1.4	41
384	Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines, 2019, 7, 18.	1.4	38
385	B cell checkpoints in autoimmune rheumatic diseases. Nature Reviews Rheumatology, 2019, 15, 303-315.	3.5	62
386	Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. Journal of Clinical Medicine, 2019, 8, 493.	1.0	13
387	The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Frontiers in Immunology, 2019, 10, 33.	2.2	135
388	Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987995.	0.5	5
391	A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflammation Research, 2019, 68, 25-38.	1.6	104
392	Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain, 2019, 142, 120-132.	3.7	81
393	The applications of anti-CD20 antibodies to treat various B cells disorders. Biomedicine and Pharmacotherapy, 2019, 109, 2415-2426.	2.5	43
394	Ocrelizumab for the treatment of multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 97-108.	1.4	19
395	Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients. Cells, 2019, 8, 12.	1.8	109
396	Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs, 2019, 33, 61-78.	2.2	21
397	Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Safety, 2019, 42, 633-647.	1.4	18
398	Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Multiple Sclerosis and Related Disorders, 2019, 27, 397-399.	0.9	14
399	Short-chain fatty acids and gut microbiota in multiple sclerosis. Acta Neurologica Scandinavica, 2019, 139, 208-219.	1.0	73
400	Multiple sclerosis â€" the remarkable story of a baffling disease. Reviews in the Neurosciences, 2019, 30, 511-526.	1.4	13
401	B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy, 2019, 19, 261-271.	1.4	50

#	ARTICLE	IF	CITATIONS
402	The role of B cells in multiple sclerosis: Current and future therapies. Cellular Immunology, 2019, 339, 10-23.	1.4	29
403	Considerable Therapeutic Strategies for Treatment of Genetic Defects Govern Neurovascular Disease. Ecoproduction, 2019, , 229-250.	0.8	0
404	Metabolic defects in multiple sclerosis. Mitochondrion, 2019, 44, 7-14.	1.6	42
405	Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Multiple Sclerosis Journal, 2019, 25, 235-245.	1.4	103
406	B-Cell Therapies in Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a032037.	2.9	60
407	The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a029108.	2.9	17
408	Efficacy of rituximab in refractory RRMS. Multiple Sclerosis Journal, 2019, 25, 828-836.	1.4	28
409	Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	1.4	38
410	Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Multiple Sclerosis and Related Disorders, 2020, 37, 101468.	0.9	44
412	The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. Neurotherapeutics, 2020, 17, 1768-1784.	2.1	15
413	Autoantigen Tetramer Silences Autoreactive B Cell Populations. Molecular Pharmaceutics, 2020, 17, 4201-4211.	2.3	1
414	Avanços no tratamento da esclerose múltipla através do anticorpo monoclonal Ocrelizumabe. Medicina, 2020, 53, 35-41.	0.0	1
415	Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique, 2020, 176, 804-822.	0.6	9
416	A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732096450.	0.5	13
417	Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sciences, 2020, 10, 758.	1.1	55
418	Unraveling B lymphocytes in CNS inflammatory diseases. Neurology, 2020, 95, 733-744.	1.5	10
419	A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22932-22943.	3.3	119
420	Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opinion on Drug Safety, 2020, 19, 1069-1094.	1.0	26

#	Article	IF	Citations
422	Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plasticity, 2020, 5, 123-133.	1.9	44
424	Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients. Journal of the Neurological Sciences, 2020, 415, 116973.	0.3	17
425	The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.. Multiple Sclerosis and Related Disorders, 2020, 44, 102279.	0.9	77
426	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews, 2020, 33, .	5.7	68
427	Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 4312.	1.8	38
428	Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts â€" the CONFIDENCE study protocol. BMC Neurology, 2020, 20, 95.	0.8	20
429	The impact of multiple sclerosis relapses on worsening over the long term; insights in the treatment era. Journal of the Neurological Sciences, 2020, 413, 116773.	0.3	3
430	Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	13
431	Effect of Rituximab on Expanded Disability Status Scale and Relapse Rate in Multiple Sclerosis Patients. Journal of Molecular Neuroscience, 2020, 70, 1165-1168.	1.1	4
432	Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. Multiple Sclerosis and Related Disorders, 2020, 40, 101980.	0.9	18
433	Natural killer cells in multiple sclerosis: A review. Immunology Letters, 2020, 222, 1-11.	1.1	34
434	A critical analysis of helminth immunotherapy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1448-1458.	1.4	21
435	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. CNS Drugs, 2020, 34, 269-280.	2.7	49
436	The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. Current Medical Research and Opinion, 2020, 36, 1145-1156.	0.9	5
437	Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis. Immunology and Cell Biology, 2020, 98, 549-562.	1.0	10
438	The role of B cells in the immunopathogenesis of multiple sclerosis. Immunology, 2020, 160, 325-335.	2.0	22
439	A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 420-429.	1.4	73
440	Role of B Cells in Multiple Sclerosis and Related Disorders. Annals of Neurology, 2021, 89, 13-23.	2.8	123

#	ARTICLE	IF	CITATIONS
441	Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?. Drug Discovery Today, 2021, 26, 416-428.	3.2	16
442	Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics, 2021, 18, 364-377.	2.1	20
443	DNA methylation signatures of autoimmune diseases in human B lymphocytes. Clinical Immunology, 2021, 222, 108622.	1.4	21
444	Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. British Journal of Clinical Pharmacology, 2021, 87, 2511-2520.	1.1	39
445	Regulation of neuroinflammation by B cells and plasma cells. Immunological Reviews, 2021, 299, 45-60.	2.8	19
446	Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Multiple Sclerosis Journal, 2021, 27, 1066-1076.	1.4	26
447	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Multiple Sclerosis Journal, 2021, 27, 331-346.	1.4	26
448	Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines, 2021, 9, 99.	2.1	24
450	B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF. Scientific Reports, 2021, 11, 2890.	1.6	11
451	Targeting B cells in multiple sclerosis. Current Opinion in Neurology, 2021, 34, 295-302.	1.8	5
452	Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis. NeurologÃa, 2021, , .	0.3	3
453	Pertussis Toxin Inhibits Encephalitogenic T-Cell Infiltration and Promotes a B-Cell-Driven Disease during Th17-EAE. International Journal of Molecular Sciences, 2021, 22, 2924.	1.8	4
454	CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e973.	3.1	6
455	A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20â€"Yet Progress Continues. Neurotherapeutics, 2021, 18, 1602-1622.	2.1	12
456	Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. Expert Opinion on Drug Safety, 2021, 20, 925-936.	1.0	10
458	Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 49, 102787.	0.9	29
459	The Ins and Outs of Central Nervous System Inflammationâ€"Lessons Learned from Multiple Sclerosis. Annual Review of Immunology, 2021, 39, 199-226.	9.5	30
460	Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996-2019). Multiple Sclerosis and Related Disorders, 2021, 50, 102835.	0.9	5

#	ARTICLE	IF	CITATIONS
461	CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study. Brain Pathology, 2021, 31, e12969.	2.1	10
462	Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis. Frontiers in Immunology, 2021, 12, 676686.	2.2	20
463	Update on treatment in multiple sclerosis. Presse Medicale, 2021, 50, 104068.	0.8	32
464	Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology. Therapeutics and Clinical Risk Management, 2021, Volume 17, 765-776.	0.9	9
465	B-cell depletion therapy for multiple sclerosis. Immunological Medicine, 2022, 45, 54-62.	1.4	8
466	A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile. PharmacoEconomics - Open, 2021, 5, 635-647.	0.9	3
467	MANF Is Neuroprotective in Early Stages of EAE, and Elevated in Spinal White Matter by Treatment With Dexamethasone. Frontiers in Cellular Neuroscience, 2021, 15, 640084.	1.8	7
468	Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique, 2021, 177, 980-994.	0.6	13
469	Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Multiple Sclerosis Journal, 2022, 28, 1121-1125.	1.4	34
470	Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis. Human Antibodies, 2021, 29, 255-262.	0.6	1
471	Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. Journal of Neurology, 2022, 269, 1316-1334.	1.8	46
472	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. Annals of Internal Medicine, 2021, 174, 1572-1585.	2.0	273
473	Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models. Immunology, 2021, 164, 450-466.	2.0	18
474	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. CNS Drugs, 2021, 35, 985-997.	2.7	26
475	Targeting Antigen-Presenting Cells in Multiple Sclerosis Treatment. Applied Sciences (Switzerland), 2021, 11, 8557.	1.3	2
476	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology, 2021, 97, e1546-e1559.	1.5	75
477	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 729-738.	4.9	89
479	B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. Journal of Neuroimmunology, 2021, 359, 577676.	1.1	8

#	ARTICLE	IF	CITATIONS
480	The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis. IBRO Neuroscience Reports, 2021, 11, 103-111.	0.7	6
481	Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 595547.	1.1	25
482	Inflammation in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110076.	1.5	47
483	Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases. Methods in Molecular Biology, 2016, 1371, 143-155.	0.4	4
484	Saliency Based Deep Neural Network for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI. Lecture Notes in Computer Science, 2020, , 108-118.	1.0	2
485	Differential Diagnosis in Hypogammaglobulinemia. Rare Diseases of the Immune System, 2019, , 235-252.	0.1	1
486	B-cell depletion. , 2015, , 472-478.		2
487	B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight, 2016, 1, e87234.	2.3	51
488	Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight, 2017, 2, .	2.3	84
489	B cell exchange across the blood-brain barrier in multiple sclerosis. Journal of Clinical Investigation, 2012, 122, 4533-4543.	3.9	211
490	Severe, Highly Active, or Aggressive Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 761-784.	0.4	29
491	Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. Wellcome Open Research, 0, 1, 10.	0.9	11
492	Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. Wellcome Open Research, 2016, 1, 10.	0.9	22
493	Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program. PLoS ONE, 2014, 9, e87379.	1.1	71
494	A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e105421.	1.1	81
495	Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-Î± and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2016, 11, e0146971.	1.1	8
496	Pathogenesis and Progression of Multiple Sclerosis: The Role of Arachidonic Acidâ€"Mediated Neuroinflammation. , 0, , 111-124.		11
497	Current and Future Therapies Targeting the Immune System in Multiple Sclerosis. Current Pharmaceutical Biotechnology, 2014, 15, 276-296.	0.9	33

#	ARTICLE	IF	CITATIONS
498	Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-352.	1.3	24
499	Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines, 2021, 9, 12.	2.1	28
500	Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.		

#	Article	IF	Citations
517	Musculoskeletal ultrasound in neurology. Neurologie Pro Praxi, 2017, 18, 287-290.	0.0	1
518	Pathophysiologisch ansetzende Therapie. , 2018, , 261-352.		0
519	Monoclonal antibodies have become a great challenge in treating Multiple Sclerosis. Neurologie Pro Praxi, 2018, 19, 123-129.	0.0	1
520	Ocrelizumab. Pharma-Kritik (discontinued), 2018, 40, .	0.0	0
521	Therapie der Multiplen Sklerose: Management der Nebenwirkungen. Deutsches A&#x0308;rzteblatt International, 0, , .	0.6	1
522	Ocrelizumab - pharmacoloical profile. Neurologie Pro Praxi, 2018, 19, 380-386.	0.0	0
523	Multiple Sklerose: Therapie. Springer Reference Medizin, 2019, , 1-25.	0.0	0
524	Ocrelizumab â€" a monoclonal antibody â€" in the treatment of adult patients with multiple sclerosis: a systematic review. Farmakoekonomika, 2018, 11, 43-56.	0.4	0
525	Immunologie de la sclÃ©rose en plaques. , 2019, , 151-198.		0
526	THE FIRST DOSING OCRELIZUMAB EXPERIENCE OF A NEUROLOGY CLINIC: A RETROSPECTIVE STUDY. Noropsikiyatri Arsivi, 2019, 58, 52-56.	0.2	1
528	Epidemiology and Genetics. Current Clinical Neurology, 2020, , 71-87.	0.1	1
529	Longterm safety of Ocrelizumab in Multiple Sclerosis treatment. Neurologie Pro Praxi, 2020, 21, 291-293.	0.0	0
530	Interferon-beta injection in multiple sclerosis patients is related to the induction of headache and flu-like pain symptoms: a systematic review and meta-analysis of randomised controlled trials. Current Neuropharmacology, 2021, 19, .	1.4	1
531	A review: Multiple Sclerosis Treatment: Current Strategies and Future Hopes. Alexandria Journal of Veterinary Sciences, 2020, 66, 30.	0.0	0
532	Multiple Sklerose: Therapie. Springer Reference Medizin, 2020, , 1099-1123.	0.0	0
537	Mass cytometry provides unprecedented insight into the role of B cells during the pathogenesis of multiple sclerosis. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 12-14.	0.1	0
538	Efficacy and safety of ocrelizumab in patients with relapsingâ€remitting multiple sclerosis with suboptimal response to prior diseaseâ€modifying therapies: A primary analysis from the phase 3b CASTING singleâ€arm, openâ€label trial. European Journal of Neurology, 2022, 29, 790-801.	1.7	15
539	Antiâ€B cell therapies in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2021, 12, 228-237.	0.5	1

#	Article	IF	Citations
540	Multiple sclerosis review. P and T, 2012, 37, 175-84.	1.0	284
541	The Latest Innovations in the Drug Pipeline for Multiple Sclerosis. American Health and Drug Benefits, 2015, 8, 448-53.	0.5	12
542	Clinical and radiologic manifestation B-cell mediated autoimmune diseases of central nervous system. American Journal of Clinical and Experimental Immunology, 2020, 9, 28-40.	0.2	1
543	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. Cells, 2021, 10, 3177.	1.8	16
544	The Role of Ocrelizumab in Multiple Sclerosis Treatment. Archives of Pharmacy Practice, 2021, 12, 117-120.	0.2	2
545	Novel contributors to B cell activation during inflammatory CNS demyelination; An oNGOing process. International Journal of Medical Sciences, 2022, 19, 164-174.	1.1	1
546	Severe Ocrelizumab-Induced Enterocolitis Treated Successfully With Ustekinumab. ACG Case Reports Journal, 2022, 9, e00742.	0.2	5
547	Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110693.	0.5	5
548	Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology, 2022, 18, 105-114.	1.3	1
549	Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders. Frontiers in Immunology, 2021, 12, 788830.	2.2	18
550	Treatment of multiple sclerosis in children: A brief overview. Clinical Immunology, 2022, 237, 108947.	1.4	4
551	Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications â€" A pilot study. Multiple Sclerosis and Related Disorders, 2022, 59, 103560.	0.9	11
552	Effectiveness of Anti-Cluster of Differentiation 20 as a Disease-Modifying Therapy in Multiple Sclerosis Across Its Different Phenotypes at the University Hospital of Caen. Cureus, 2022, 14, e22120.	0.2	0
554	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2022, 207, 263-271.	1.1	14
555	Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 3172.	1.8	4
556	Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. Neurotherapeutics, 2022, 19, 774-784.	2.1	6
557	Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. Journal of Clinical Medicine, 2022, 11, 2081.	1.0	6
558	Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease. , 2022, 238, 108180.		5

#	Article	IF	Citations
559	Long-term data of multiple sclerosis treatment with ocrelizumab - eficacy, safety and clinical experience. Neurologie Pro Praxi, 2021, 22, 477-480.	0.0	0
560	Extended dosing of monoclonal antibodies in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2001-2009.	1.4	16
562	Specific hypomethylation programs underpin B cell activation in early multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
563	The role of B cells and their interactions with stromal cells in the context of inflammatory autoimmune diseases. Autoimmunity Reviews, 2022, 21, 103098.	2.5	9
564	Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210920.	1.5	5
565	Management of multiple sclerosis using disease-modifying therapies: a clinical review. British Journal of Neuroscience Nursing, 2022, 18, 84-96.	0.1	1
566	Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Molecular Pharmaceutics, 2022, 19, 1952-1976.	2.3	5
567	Ocrelizumab for multiple sclerosis. The Cochrane Library, 2022, 2022, CD013247.	1.5	9
568	Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis. CNS Drugs, 2022, 36, 569-589.	2.7	6
569	Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study. International Journal of Cardiology, 2022, 362, 153-157.	0.8	2
570	Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. Neurotherapeutics, 2022, 19, 1216-1228.	2.1	3
571	Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 986-994.	0.9	18
572	Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
573	An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis. Wiener Medizinische Wochenschrift, 2022, 172, 359-364.	0.5	4
574	Ocrelizumab - long-term efficacy and safety in real-world clinical practice in patients with relapsing-remitting multiple sclerosis. Neurologie Pro Praxi, 2022, 23, 233-237.	0.0	0
575	FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis. BMJ Open, 2022, 12, e058506.	0.8	5
576	Recent advances in the management of multiple sclerosis. International Journal of Basic and Clinical Pharmacology, 0, , .	0.0	0
577	Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Practical Neurology, 2023, 23, 6-14.	0.5	13

#	Article	IF	Citations
578	Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis. Journal of Clinical Medicine, 2022, 11, 4288.	1.0	2
579	Epstein–Barr virus and multiple sclerosis. Nature Reviews Microbiology, 2023, 21, 51-64.	13.6	151
581	Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 67, 104164.	0.9	1
582	Ocrelizumab in tumefactive multiple sclerosis onset. A case report. Neuroimmunology Reports, 2022, 2, 100122.	0.2	1
583	The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis. CNS Drugs, 2022, 36, 1155-1170.	2.7	1
584	Epigenetic regulation of B cells and its role in autoimmune pathogenesis. , 2022, 19, 1215-1234.		15
585	Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2022, 22, 721-734.	2.0	17
586	Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	0
587	Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study. Multiple Sclerosis and Related Disorders, 2022, 68, 104246.	0.9	3
588	Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients. International Journal of Molecular Sciences, 2022, 23, 13759.	1.8	2
589	Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 2022, 15, e252140.	0.2	4
590	AQP4 as a vintage autoantigen: what do we know till now?. Heliyon, 2022, 8, e12132.	1.4	0
591	Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	14
592	CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	7
593	Dual Role of B Cells in Multiple Sclerosis. International Journal of Molecular Sciences, 2023, 24, 2336.	1.8	7
594	Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	1
595	Ocrelizumab Impairs the Phenotype and Function of Memory CD8^{+} T Cells. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	4
596	Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis. Journal of Drug Delivery Science and Technology, 2023, 81, 104220.	1.4	3

#	ARTICLE	IF	CITATIONS
597	B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Frontiers in Immunology, 0, 14, .	2.2	7
598	The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses, 2023, 15, 782.	1.5	26
599	Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Frontiers in Immunology, 0, 14, .	2.2	15
600	Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes. Communications Biology, 2023, 6, .	2.0	4
601	Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk. Biology, 2023, 12, 587.	1.3	0
602	Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2023, 123, 37.	0.1	2
610	Bedside to benchside translation with the targeting of the BAFF/APRIL axis in neurological autoimmune disorders. , 2023, , 425-434.		0
611	Monoclonal antibodies in multiple sclerosis treatment. , 2023, , 191-207.		0
619	Anti-CD20 antibodies in glomerular diseases, their resistance and reversal approaches. , 2024, , 313-334.		0
620	Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases. , 2024, , 375-400.		0
621	Clinical efficacy of anti-CD20 antibodies in autoimmune diseases. , 2024, , 273-298.		0